Abbott has obtained a CE mark for a dual glucose-ketone monitoring system, which is reportedly the world's first such technology. The system is intended for people with diabetes and may help prevent diabetic ketoacidosis. The CE mark allows Abbott to market the system in Europe, although the impact on the company's stock is uncertain.